Tourmaline Bio, Inc.
TRMLDelisted Oct 28, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827506
Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in Tourmaline Bio, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 107
- +7 vs. Q4 2024
- Shares held
- 23.9M
- +1.16M (+5.1%) vs. Q4 2024
- Total value
- $364.3M
- −$97.8M (−21.2%) vs. Q4 2024
- New holders
- 19
- 34 more added
- Sold out
- 12
- 31 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRML on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 134 | $1.03B |
| Q2 2025 | 109 | $384.8M |
| Q1 2025 | 107 | $364.3M |
| Q4 2024 | 101 | $463.6M |
| Q3 2024 | 92 | $540.7M |
| Q2 2024 | 84 | $272.0M |
| Q1 2024 | 96 | $469.9M |
| Q4 2023 | 54 | $338.2M |
| Q3 2023 | 49 | $77.1M |
| Q2 2023 | 58 | $79.7M |
| Q1 2023 | 54 | $50.6M |
| Q4 2022 | 54 | $27.4M |
| Q3 2022 | 56 | $72.1M |
| Q2 2022 | 59 | $130.4M |
| Q1 2022 | 51 | $286.9M |
| Q4 2021 | 51 | $456.7M |
| Q3 2021 | 48 | $349.4M |
| Q2 2021 | 50 | $379.4M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Tourmaline Bio, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 1,190,810 | $18.1M | 0.00% | +84,685+7.7% | Added |
| Pfizer Inc | 1,272,214 | $19.4M | 3.86% | 00.0% | Unchanged |
| QVT Financial LP | 1,473,369 | $22.4M | 2.14% | +762,094+107.1% | Added |
| TCG Crossover Management, LLC | 1,477,593 | $22.5M | 3.07% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,792,208 | $27.3M | 0.00% | −11,692−0.6% | Reduced |
| Avoro Capital Advisors LLC | 2,425,000 | $36.9M | 0.58% | +202,778+9.1% | Added |
| Ra Capital Management, L.P. | 2,538,925 | $38.6M | 0.64% | 00.0% | Unchanged |
| RTW Investments, LP | 0 | $0 | 0.00% | −736,681−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −126,400−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −72,335−100.0% | Sold out |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −29,844−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −17,887−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −15,267−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −10,198−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −9,903−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −3,157−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −109−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −56−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |